206 related articles for article (PubMed ID: 24470751)
1. Does fesoterodine have a role in the treatment of poorly managed patients with overactive bladder?
Morris V; Wagg A
Drug Des Devel Ther; 2014; 8():113-9. PubMed ID: 24470751
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of fesoterodine compared with extended-release tolterodine in men and women with overactive bladder.
Ginsberg D; Schneider T; Kelleher C; Van Kerrebroeck P; Swift S; Creanga D; Martire DL
BJU Int; 2013 Aug; 112(3):373-85. PubMed ID: 23826844
[TBL] [Abstract][Full Text] [Related]
3. Fesoterodine clinical efficacy and safety for the treatment of overactive bladder in relation to patient profiles: a systematic review.
Chapple C; Oelke M; Kaplan SA; Scholfield D; Arumi D; Wagg AS
Curr Med Res Opin; 2015 Jun; 31(6):1201-43. PubMed ID: 25798911
[TBL] [Abstract][Full Text] [Related]
4. Characteristics of antimuscarinic responders versus suboptimal responders in a randomized clinical trial of patients with overactive bladder symptoms.
Grenabo L; Herschorn S; Kaplan SA; Cardozo L; Scholfield D; Arumi D; Carlsson M; Chapman D; Ntanios F
Curr Med Res Opin; 2017 Oct; 33(10):1731-1736. PubMed ID: 28758802
[TBL] [Abstract][Full Text] [Related]
5. Review of the efficacy and safety of fesoterodine for treating overactive bladder and urgency urinary incontinence in elderly patients.
Wagg A; Oelke M; Angulo JC; Scholfield D; Arumi D
Drugs Aging; 2015 Feb; 32(2):103-25. PubMed ID: 25673122
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and tolerability of fesoterodine versus tolterodine in older and younger subjects with overactive bladder: a post hoc, pooled analysis from two placebo-controlled trials.
DuBeau CE; Morrow JD; Kraus SR; Creanga D; Bavendam T
Neurourol Urodyn; 2012 Nov; 31(8):1258-65. PubMed ID: 22907761
[TBL] [Abstract][Full Text] [Related]
7. [A role of fesoterodine in treatment of overactive bladder].
Kupriyanov YA; Kasyan GR; Pushkar DY
Urologiia; 2018 Dec; (6):155-162. PubMed ID: 30742396
[TBL] [Abstract][Full Text] [Related]
8. Fesoterodine fumarate.
Gomelsky A; Dmochowski RR
Drugs Today (Barc); 2010 Feb; 46(2):81-90. PubMed ID: 20393636
[TBL] [Abstract][Full Text] [Related]
9. Comparison of fesoterodine and tolterodine in patients with overactive bladder.
Chapple CR; Van Kerrebroeck PE; Jünemann KP; Wang JT; Brodsky M
BJU Int; 2008 Nov; 102(9):1128-32. PubMed ID: 18647298
[TBL] [Abstract][Full Text] [Related]
10. Fesoterodine: a new agent for treating overactive bladder.
Ellsworth P; Berriman SJ; Brodsky M
Am J Manag Care; 2009 Mar; 15(4 Suppl):S115-7. PubMed ID: 19355800
[TBL] [Abstract][Full Text] [Related]
11. Comparison of fesoterodine and tolterodine extended release for the treatment of overactive bladder: a head-to-head placebo-controlled trial.
Herschorn S; Swift S; Guan Z; Carlsson M; Morrow JD; Brodsky M; Gong J
BJU Int; 2010 Jan; 105(1):58-66. PubMed ID: 20132103
[TBL] [Abstract][Full Text] [Related]
12. Tolterodine extended release in the treatment of male OAB/storage LUTS: a systematic review.
Gacci M; Novara G; De Nunzio C; Tubaro A; Schiavina R; Brunocilla E; Sebastianelli A; Salvi M; Oelke M; Gravas S; Carini M; Serni S
BMC Urol; 2014 Oct; 14():84. PubMed ID: 25348235
[TBL] [Abstract][Full Text] [Related]
13. The cost-effectiveness of solifenacin vs fesoterodine, oxybutynin immediate-release, propiverine, tolterodine extended-release and tolterodine immediate-release in the treatment of patients with overactive bladder in the UK National Health Service.
Cardozo L; Thorpe A; Warner J; Sidhu M
BJU Int; 2010 Aug; 106(4):506-14. PubMed ID: 20132203
[TBL] [Abstract][Full Text] [Related]
14. A pooled analysis of the efficacy of fesoterodine for the treatment of overactive bladder, and the relationship between safety, co-morbidity and polypharmacy in patients aged 65 years or older.
Wagg A; Arumi D; Herschorn S; Angulo Cuesta J; Haab F; Ntanios F; Carlsson M; Oelke M
Age Ageing; 2017 Jul; 46(4):620-626. PubMed ID: 28057620
[TBL] [Abstract][Full Text] [Related]
15. Multicriteria Decision Analysis Applied to the Clinical Use of Pharmacotherapy for Overactive Bladder Symptom Complex.
Chapple CR; Mironska E; Wagg A; Milsom I; Diaz DC; Koelbl H; Pushkar D; Tubaro A; De Ridder D; Chartier-Kastler E; Phillips LD
Eur Urol Focus; 2020 May; 6(3):522-530. PubMed ID: 31623981
[TBL] [Abstract][Full Text] [Related]
16. Fesoterodine for the treatment of overactive bladder.
Tzefos M; Dolder C; Olin JL
Ann Pharmacother; 2009 Dec; 43(12):1992-2000. PubMed ID: 19920160
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and tolerability of fesoterodine in women with overactive bladder.
Sand PK; Morrow JD; Bavendam T; Creanga DL; Nitti VW
Int Urogynecol J Pelvic Floor Dysfunct; 2009 Jul; 20(7):827-35. PubMed ID: 19495545
[TBL] [Abstract][Full Text] [Related]
18. Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trial.
Kaplan SA; Roehrborn CG; Rovner ES; Carlsson M; Bavendam T; Guan Z
JAMA; 2006 Nov; 296(19):2319-28. PubMed ID: 17105794
[TBL] [Abstract][Full Text] [Related]
19. Safety and efficacy of fesoterodine fumarate in patients with overactive bladder: results of a post-marketing surveillance study in Korea.
Kim TH; Lee SE; Lee HE; Lee KS
Curr Med Res Opin; 2016 Aug; 32(8):1361-6. PubMed ID: 27046653
[TBL] [Abstract][Full Text] [Related]
20. Diary and patient-reported outcomes in patients with severe overactive bladder switching from tolterodine extended release 4 mg/day to solifenacin treatment: An open-label, flexible-dosing, multicentre study.
Swift SE; Siami P; Forero-Schwanhaeuser S
Clin Drug Investig; 2009; 29(5):305-16. PubMed ID: 19366272
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
